Columbia Advisory Partners’s Humacyte HUMA Stock Holding History

Columbia Advisory Partners’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.6K	Hold	19,958	–	–	0.01%	110
2026 Q1	$12.1K	Buy	19,958 +4,273	+27%	+$4.44K	0.01%	91
2025 Q4	$15.1K	Hold	15,685	–	–	0.01%	89
2025 Q3	$27.3K	Hold	15,685	–	–	0.02%	88
2025 Q2	$32.8K	Hold	15,685	–	–	0.02%	78
2025 Q1	$26.7K	Buy	+15,685	New	+$58.9K	0.02%	70

Other funds holding HUMA

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

UAS

United Asset Strategies Garden City, New York $1.41B AUM 27.73% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

CIA

Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

CWA

Clarus Wealth Advisors Peoria, Arizona $260M AUM 27.97% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

VMMC

V.M. Manning & Co Greenville, South Carolina $117M AUM

TCOK

Trust Company of Kansas Wichita, Kansas $195M AUM 27.88% 1-Year Est. Return

Columbia Advisory Partners's HUMA Position: Q2 2026 in Review

Columbia Advisory Partners held its Humacyte (HUMA) position steady in Q2 2026 at 19,958 shares worth $15.6K. The position accounts for 0.01% of the portfolio, ranked #110.

Columbia Advisory Partners first reported a position in HUMA in Q1 2025 and has held it in 6 quarters since. The position peaked at $32.8K in Q2 2025. 38 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Columbia Advisory Partners held 19,958 shares of Humacyte worth $15.6K as of Q2 2026.
Columbia Advisory Partners left its Humacyte share count unchanged in Q2 2026.
Humacyte made up 0.01% of Columbia Advisory Partners's portfolio in Q2 2026, its #110 holding.
Columbia Advisory Partners first reported a position in Humacyte in Q1 2025 and has held it in 6 quarters since.
Columbia Advisory Partners's Humacyte position peaked at $32.8K in Q2 2025.
38 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Columbia Advisory Partners's 13F filing for Q2 2026, filed 23 Jul 2026.